Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MB07133

Small molecule · Inhibitor of DNA polymerase · developed by Ligand Pharmaceuticals

Phase 1/2 Most advanced trial (none active)
LGND Developer
1 Registered trials

What is MB07133?

MB07133 is a prodrug of the monophosphate form of the antimetabolite cytarabine, designed to deliver cytarabine to the liver, where a liver kinase converts it to the triphosphate form. The active metabolite competes with cytidine for incorporation into DNA and inhibits DNA polymerase, slowing DNA synthesis. It is studied in hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
DNA polymerase
Mechanism
Inhibitor of DNA polymerase
Pathways
DNA synthesis, tumor cell proliferation
Therapy area
Oncology
Developer
Ligand Pharmaceuticals (LGND)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00073736 Phase 1/2 Hepatocellular Carcinoma Completed LGND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular Carcinoma

More from Ligand Pharmaceuticals

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LGND page.

Follow LGND, the company behind MB07133

See LGND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LGND catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.